Nikkei (Free subscription) | 06/27/2008
Eisai Boss Sees MGI Pharma As Playing Major Profit RoleTOKYO (Nikkei)--Eisai Co. (4523) has purchased U.S. bioventure MGI Pharma Inc. as part of its strategy to bring about a new growth spurt now that patents on its major moneymakers are set to expire in a few years, President Haruo Naito said in a recent interview.
Red Orbit (Free subscription) | 03/03/2008
Eisai, its US subsidiary MGI Pharma, and Helsinn Healthcare have reported that the FDA has approved Aloxi injection for the prevention of postoperative nausea and vomiting or PONV for up to 24 hours following surgery.
Red Orbit (Free subscription) | 03/03/2008
WOODCLIFF LAKE, N.J., March 2 /PRNewswire/ -- Eisai Corporation of North America, its U.S. subsidiary, MGI PHARMA, INC., and Helsinn Healthcare SA today announced that the U.S.
Pharmalot (Free subscription) | 02/06/2008
In a letter to Pharmion ceo Pat Mahaffy, Steven Cohen's SAC Capital advisors contends that the biotech could be worth more as a standalone company than Celgene’s $2.9 billion offer, depending upon the results of a clinical trial for a rival's key drug. MGI Pharma is testing Dacogen, a cancer med similar to Pharmion's Vidaza, [...]
Nikkei (Free subscription) | 01/29/2008
Eisai Completes $3.9bn Acquisition Of U.S. Drugmaker MGI PharmaTOKYO (Nikkei)--Eisai Co. (4523) said Tuesday it has completed the purchase of Minnesota-based drugmaker MGI Pharma Inc. for about 3.9 billion dollars, or 410 billion yen.
The Minneapolis/St. Paul Business Journal (Free subscription) | 01/28/2008
Pharmaceutical company Eisai Co. completed its $3.9 billion purchase of MGI Pharma Inc., the Japanese company said Monday.
Red Orbit (Free subscription) | 01/26/2008
Eisai Co., Ltd. (Tokyo, TSE 4523) ("Eisai"), a research-based human health care (hhc) company, today announced the completion of the offer by its indirect wholly-owned subsidiary, Jaguar Acquisition Corp. ("Jaguar"), to purchase all outstanding shares of the common stock of MGI PHARMA, INC.
Nikkei (Free subscription) | 01/23/2008
Eisai Wraps Up Tender Offer For U.S. Firm MGI PharmaTOKYO (Nikkei)--Drugmaker Eisai Co. (4523) completed its tender offer for U.S. firm MGI Pharma Inc. Wednesday, securing a 96.1% interest at the offer price of 41 dollars a share.
Red Orbit (Free subscription) | 01/21/2008
MGI Pharma has announced that results from a st
The Minneapolis/St. Paul Business Journal (Free subscription) | 01/17/2008
MGI Pharma Inc.'s $3.9 billion deal to be bought by Japanese pharmaceutical company Eisai Co. is now a step closer to being completed.
Market Watch (Free subscription) | 12/26/2007
SAN FRANCISCO (MarketWatch) -- MGI Pharma Inc. said late Wednesday that its senior subordinated convertible notes due 2024 will become convertible to $41 a share as outlined by the company's acquisition by Eisai Co. Each $1,000 in notes will be redeemable for $974.33 in cash, representing 23.7642 MGI shares after Jan. 8. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets...
Red Orbit (Free subscription) | 12/19/2007
MGI Pharma has reported that that its new drug application for Aquavan injection was accepted for filing by the FDA. Aquavan is an investigational drug that is being studied as a sedative-hypnotic agent in patients undergoing diagnostic or therapeutic procedures.
FeedTheBull.com - published (Free subscription) | 12/18/2007
Eisai's ambitious "Dramatic Leap Plan," trying to grow its presence worldwide, particularly in the oncology field, has brought them to MGI Pharma. MGI makes drugs like Aloxi, which is used to prevent chemotherapy-induced nausea, and Hexalen, which is used to treat ovarian cancer. Morningstar analyst Brian Laegeler said Eisai is paying a hefty price. "The desperation of big pharma rivals looking to...
The Minneapolis/St. Paul Business Journal (Free subscription) | 12/17/2007
MGI Pharma Inc. said the FDA will review a new sedative the company developed for minor surgeries Monday.
Chemical and Engineering News (Free subscription) | 12/17/2007
Japanese firm is the latest to expand by buying a U.S. biotech firm.
